Compare IONQ Inc (IONQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Johnson & Johnson — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 38.7× IONQ Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Johnson & Johnson for 129 Days on average.
| IONQ | JNJ | |
|---|---|---|
Market Cap | $15.98B | $618.09B |
Volume | 22,848,240 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $82.09 | $278.43 |
52-Week Low | $26.59 | $186.00 |
Typical Hold Time | 33 Days | 129 Days |
Enterprise Value | $13.92B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.89, down 3.51% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, with a high P/S ratio of 54.74. Recent news highlights Bank of America's Buy rating and $60 price target, citing IonQ's semiconductor-based quantum computing approach as a key growth driver.
The stock presents high-risk, high-reward potential with strong analyst optimism but faces significant execution risks amid widening losses. Upside depends on scaling quantum technology profitably, while downside risks include cash burn and competitive threats. The consensus price target of $62.75 suggests substantial upside if growth targets are met.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
